Aspirin in Reducing Events in the Elderly

Hennepin Healthcare Research Institute
Active, not recruiting ID
For more information, see NCT01038583
ASPREE-XT is a post-treatment, longitudinal observational follow-up study of ASPREE participants [ASPREE Investigator Group, 2013;; McNeil et al 2017]. Although the ASPREE trial medication was ceased, the study activity was not stopped and ASPREE participants are continuing with scheduled visits and phone calls. An observational follow-up phase (ASPREE-XT), began in January, 2018. This will enable the monitoring of possible delayed effects of aspirin treatment, primarily on cancer incidence, metastases and mortality. In addition to monitoring the incidence of malignancy within the ASPREE cohort, the opportunity will be taken to observe any other residual effects of aspirin on the endpoints being monitored in the cohort. Continuity of contact with study participants is the key to retention of the cohort for any ongoing or future studies.
Placebo, 100 mg enteric-coated aspirin
Functional Disability, Dementia, Heart Disease, Stroke, Cancer, Bleeding, Depression
John McNeil, MBBS, PHD, Anne Murray, MD, MSc

See list of participating sites